by MM360 Staff | Jan 4, 2026 | Publications
Br J Haematol. 2026 Jan 2. doi: 10.1111/bjh.70323. Online ahead of print. ABSTRACT High-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM). A substantial...
by MM360 Staff | Dec 15, 2025 | Publications
Curr Res Transl Med. 2025 Dec 2;74(1):103559. doi: 10.1016/j.retram.2025.103559. Online ahead of print. ABSTRACT BACKGROUND: Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities....
by MM360 Staff | Dec 12, 2025 | Publications
Diagnostics (Basel). 2025 Nov 21;15(23):2942. doi: 10.3390/diagnostics15232942. ABSTRACT After publication, the authors identified several errors in the manuscript, including inconsistencies between the manuscript’s reported results and the corresponding...
by MM360 Staff | Dec 12, 2025 | Publications
Cancers (Basel). 2025 Nov 21;17(23):3730. doi: 10.3390/cancers17233730. ABSTRACT BACKGROUND: Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key...
by MM360 Staff | Dec 11, 2025 | Publications
Blood Cell Ther. 2025 Nov 25;8(4):301-310. doi: 10.31547/bct-2025-008. eCollection 2025 Nov 25. ABSTRACT BACKGROUND: The optimal conditioning dose of melphalan for autologous hematopoietic stem cell transplantation (AHSCT) in multiple myeloma remains a subject of...
by MM360 Staff | Dec 9, 2025 | Publications
Cureus. 2025 Dec 3;17(12):e98368. doi: 10.7759/cureus.98368. eCollection 2025 Dec. ABSTRACT Relapsed/refractory multiple myeloma (RRMM) remains a challenging condition with a need for more effective treatment options. There are ongoing clinical trials analyzing the...
